X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CB307 is a CD137/PSMA dual inhibitor protein drug candidate administered via intravenous infusion for PSMA positive metastatic castration-resistant prostate cancer.
Lead Product(s): CB307
Therapeutic Area: Oncology Product Name: CB307
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
The proceeds will fund development of Crescendo's ongoing Phase 1b clinical trial of CB307 (tri-specific humabody) through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort in individuals with PSMA+ metastatic castration-resistant prostate cancer.
Lead Product(s): CB307,Pembrolizumab
Therapeutic Area: Oncology Product Name: CB307
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sofinnova Partners
Deal Size: $32.0 million Upfront Cash: Undisclosed
Deal Type: Financing July 24, 2023
Details:
Under the agreement, Crescendo will use ANGLE's recently launched Portrait Flex assay in its Phase 1 trial investigating the safety and efficacy of CB307, a first-in-class PSMA x CD137 half-life extended bispecific, for treating patients with PSMA positive solid tumours.
Lead Product(s): CB307
Therapeutic Area: Oncology Product Name: CB307
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: ANGLE plc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 13, 2023
Details:
Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody® VH platform to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against cancer and other diseases.
Lead Product(s): mRNA-based Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioNTech
Deal Size: $790.0 million Upfront Cash: $40.0 million
Deal Type: Collaboration January 10, 2022
Details:
The expansion will enable Takeda to access a range of Crescendo’s half-life extension Humabodies for use with its two Humabody programmes, licensed in November 2018 and July 2019.
Lead Product(s): Humabody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration December 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
